Biological relevance of adduct detection to the chemoprevention of cancer

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 4901-4912

  Sharma, Ricky A ^a,b   Farmer, Peter B ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,N2 ETHENODEOXYGUANOSINE; 1,N6 ETHENODEOXYADENOSINE; 3 (2' DEOXY B DEXTRO ERYTHROPENTAFURANOSYL)PYRIMIDO[1,2A]PURIN 10(3H) ONE; 3,N4 ETHENODEOXYCYTIDINE; 8 HYDROXYDEOXYGUANOSINE; 8,9 DIHYDRO 8 (N' 7 GUANYL) 9 HYDROXYAFLATOXIN B1; AFLATOXIN B1; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; BENZO[A]PYRENE; CARCINOGEN; CELECOXIB; CHLOROPHYLL; CYCLOOXYGENASE 2 INHIBITOR; DNA BASE; FLAVANOID; GENOMIC DNA; ISOTHIOCYANIC ACID DERIVATIVE; N2,3 ETHENODEOXYGUANOSINE; NUCLEOTIDE DERIVATIVE; OLTIPRAZ; PHOSPHORUS 32; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CLINICAL TRIAL; DIET; DISEASE MARKER; DNA ADDUCT; DNA DAMAGE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ADDUCT; PROTEIN MODIFICATION; REPRODUCIBILITY; REVIEW; SEX DIFFERENCE; STOMACH ADENOCARCINOMA; VALIDATION PROCESS;

AFLATOXIN B1; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DEOXYGUANOSINE; DIET; DNA; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; HUMANS; IMMUNOCHEMISTRY; MALE; MASS SPECTROMETRY; MODELS, CHEMICAL; NEOPLASMS; OXIDATIVE STRESS; OXYGEN; PROSTATIC NEOPLASMS; PROTEINS; RISK; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 4143078133     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0098     Document Type: Review

References (99)

1. Miller EC, Miller JA. The presence and significance of bound aminoazo dyes in the livers of rats red p-dimethylaminoazobenzene. Cancer Res 1947;7:468-80.
2. Miller EC. Studies on the formation of protein-bound derivatives of 3,4-benzpyrene in the epidermal fraction of mouse skin. Cancer Res 1951;11:100-8.
3. Auerbach C, Robson JM. Chemical production of mutations. Nature 1946;157:302.
4. Chanutin A, Gjessing EC. Effect of nitrogen mustards upon ultraviolet absorption spectrum of thymonucleate, uracil and purines. Cancer Res 1946;6:599-601.
5. Watson JD, Crick FHC. Genetical implications of the structure of deoxyribonucleic acid. Nature 1953;171:964-7.
6. Guengerich FP. Forging the links between metabolism and carcinogenesis. Mutation Res (Rev Mutation Res) 2001;488:195-209.
7. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000;21:361-70.
8. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-34.
9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 1998;90:1371-88.
10. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
11. Gescher A, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a salutary tale of failure and promise. Lancet Oncol 2001;2:371-9.
12. Alberts DS. Advanced clinical trial design: the use of surrogate end point biomarkers in cancer chemoprevention trials. In: Perry, MC, editor. American Society of Clinical Oncology Educational Book. Baltimore: Lippincott 1999. p. 76-80.
13. Einspahr JG, Alberts DS, Gapstur SM, Bostick RM, Emerson SS, Gerner EW. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomark Prev 1997;6:37-48.
14. Pepe MS, Etzioni R, Feng ZD, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
15. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000;78:199-334.
16. Sharma RA, Gescher A, Plastaras JP, et al. Cyclonxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells Carcinogenesis 2001;9:1557-60.
17. Shibutani S, Reardon JT, Suzuki N, Sancar A. Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res 2000;60:2607-10.
18. Singh R, McEwan M, Lamb JH, Santella RM, Farmer PB. An improved liquid chromatography/tandem mass spectrometry method for the determination of 8-oxo-7,8-dihydro-2′-deoxyguanosine in DNA samples using immunoaffinity column purification. Rapid Commun. Mass Spectrom 2003;17:126-34.
19. Leuratti C, Singh R, Lagneau C, Farmer PB, Marnett LJ, Shuker DEG. Determination of malondialdehyde-induced DNA damage in human tissues using an immunoslot blot assay. Carcinogenesis 1998;19:1919-24.
20. Le XC, Xing JZ, Lee J, Leadon SA, Weinfeld M. Inducible repair of thymine glycol detected by an ultrasensitive assay for DNA damage. Science 1998;280:1066-9.
21. Zhang YJ, Chen SY, Hsu TM, Santella RM. Immunohistochemical detection of malondialdehyde-DNA adducts in human oral mucosa cells. Carcinogenesis 2002;23:207-11.
22. Takahashi S, Hirose M, Tamano S, et al. Immunohistochemical detection of 8-hydroxy-2′-deoxyguanosine in paraffin-embedded sections of rat liver after carbon tetrachloride treatment. Toxicologic Pathology 1998;26:247-52.
23. Collins A, Cadet J, Epe B, Gedik C. Problems in the measurement of 8-oxoguanine in human DNA. Report of a workshop, DNA oxidation, held in Aberdeen, UK, 19-21 January, 1997. Carcinogenesis 1997;18:1833-6.
24. Churchwell MI, Beland FA, Doerge DR. Quantification of multiple DNA adducts formed through oxidative stress using liquid chromatography and electrospray tandem mass spectrometry. Chem Res Toxicol 2002;15:1295-301.
25. Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis 2000;21:353-9.
26. Sujatha N, Suryakala S, Rao BS. Enzyme immunoassay for aflatoxin B1-lysine adduct and its validation. J AOAC Int 2001;84:1465-74.
27. Wraith MJ, Watson WP, Eadsforth CV, van Sittert NJ, Tornqvist M, Wright AS. An immunoassay for monitoring human exposure to ethylene oxide. IARC Sci Publ 1988;89:271-4.
28. Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions. Carcinogenesis 2000;21:517-24.
29. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chron Dis 1982;35:581-600.
30. Anon. Biological markers in environmetal health research. Committee on Biological Markers of the National Research Council. Environ. Health Perspect 1987;74:3-9.
31. Hailer-Morrison MK, Kotler JM, Martin BD, Sugden KD. Oxidized guanine lesions as modulators of gene transcription. Altered p50 binding affinity and repair shielding by 7,8-dihydro-8-oxo-2′-deoxyguanosine lesions in the NF-kappaB promoter element. Biochemistry 2003;42:9761-70.
32. Ghosh R, Mitchell DL. Effect of oxidative DNA damage in promoter elements on transcription factor binding. Nuc Acids Res 1999;15:3213-8.
33. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995;10:674-82.
34. 1 in vitro. Pro Natl Acad Sci USA 1977;74:1870-4.
35. 1-DNA, the persistent DNA adduct in vivo. Carcinogenesis 1982;3:825-8.
36. Groopman JD, Sabbioni G, Wild CP. Molecular dosimetry of human aflatoxin exposures. In: Groopman JD, and Skipper PL, editors. Molecular Dosimetry and Human Cancer. Boca Raton FL:CRC Press, 1991. p. 303-24.
37. 1 treated rats. Cancer Res 1981;41:650-4.
38. 1 in human urine collected in Muranga district, Kenya. Carcinogenesis 1983;4:1193-5.
39. Qian G-S, Ross RK, Yu MC, et al. follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomark Prev 1994;3:3-10.
40. 1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res 1977;37:4430-8.
41. 1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc Natl Acad Sci USA 1997;94:6121-5.
42. Shimada T, Guengerich FP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci USA 1989;86:462-5.
43. Zhang YJ, Chen SY, Tsai WY, et al. Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B-1 and 4-amino-biphenyl-DNA adducts. Biomarkers 2000;5:295-306.
44. 1 metabolism. Carcinogenesis 1997;18:1729-38.
45. Feig DI, Sowers LC, Loeb LA. Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA. Proc Natl Acad Sci USA 1994;91:6609-13.
46. Henle ES, Linn S. Formation, prevention and repair of DNA damage by iron/hydrogen peroxide. J Biol Chem 1997;272:19095-8.
47. Floyd RA, Watson JJ, Wong PK, Altmiller DH, Rickard RC. Hydroxyl free radical adduct of deoxyguanosine: sensitive detection and mechanisms of formation. Free Radical Res Commun 1986;1:163-72.
48. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991;349:431-4.
49. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G→T and A→C substitutions. J Biol Chem 1992;267:166-72.
50. Moriya M. Single stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G·C→T·A transversions in simian kidney cells. Proc Natl Acad Sci USA 1993;90:1122-6.
51. Jaloszynski P, Masutani C, Hanaoka F, Perez AB, Nishimura S. 8-Hydroxyguanine in a mutational hotspot of the c-Ha-ras gene causes misreplication, 'action-at-a-distance' mutagenesis and inhibition of replication. Nuc Acids Res 2003;31:6085-95.
52. Kennedy CH, Pass HI, Mitchell JB. Expression of human MutT homologue (hMTH 1) protein in primary non-small-cell lung carcinomas and histologically normal surrounding tissue. Free Radical Biol Med 2003;34:1447-57.
53. Dedon PC, Plastaras JP, Rouzer CA, Marnett LJ. Indirect mutagenesis by oxidative DNA damage: Formation of the pyrimidopurinone adduct of deoxyguanosine by base propenal. Proc Natl Acad Sci USA 1998;95:11113-6.
54. Plummer SM, Hill KA, Festing MFW, Steward WP, Gescher A, Sharma RA. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomark Prev 2001;10:1295-9.
55. Nikolic D, van Breeman RB. DNA. oxidation induced by cyclooxygenase-2. Chem Res Toxicology 2001;14:351-4.
56. Hamada J, Nakata D, Nakae D, et al. Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation. J Natl Cancer Inst 2001;93:214-9.
57. Griffiths HR, Mistry P, Herbert KE, Lunec J. Molecular and cellular effects of ultraviolet light induced genotoxicity. Crit Rev Clin Lab Sci 1998;35:189-237.
58. Stewart MS, Cameron GS, Pence BC. Antioxidant nutrients protect against UVB-induced oxidative damage to DNA of mouse keratinocytes in culture. J Investig Dermatol 1996;106:1086-9.
59. Devasgayam TPA, Steenken S, Obendorf MSW, Schulz WA, Sies H. Formation of 8-hydroxy(deoxy)guanosine and generation of strand breaks at guanine residues in DNA by singlet oxygen. Biochemistry 1991;30:6283-9.
60. Pflaum M, Boiteux S, Epe B. Visible light generates oxidative DNA base modifications in high excess of strand breaks in mammalian cells. Carcinogenesis 1994;15:297-300.
61. Malins DC, Polissar NL, Gunselman SJ. Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH), and adenocarcinoma and have a high potential for predicting BPH and prostate cancer. Proc Natl Acad Sci USA 1997;94:259-64.
62. Malins DC, Polissar NL, Ostrander GK, Vinson MA. Single 8-oxo-guanine and 8-oxo-adenine lesions induce marked changes in the backbone structure of a 25-base DNA strand. Proc Natl Acad Sci USA 2000;97:12442-5.
63. Malins DC, Johnson PM, Wheeler TM, Barker EA, Polissar NL, Vinson MA. Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res 2001;61:6025-8.
64. Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM, Anderson KM. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci USA 2003;100:5401-6.
65. Malins DC, Hellström KE, Anderson KM, Johnson PM, Vinson MA. Antioxidant-induced changes in oxidized DNA. Proc Natl Acad Sci USA 2002;99:5937-41.
66. Waters DJ, Shen SR, Cooley DM, et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Nat Cancer Inst 2003;95:237-41.
67. Wang MY, Dhingra K, Hittelman WN, Liehr JG, de Andrade M, Li DH. Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues. Cancer Epidemiol Biomark Prev 1996;5:705-10.
68. Otteneder M, Lutz WK. Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Mutation Res (Fundamental and Molecular Mechanisms of Mutagenesis) 1999;424:237-47.
69. Leuratti C, Watson MA, Deag EJ, et al. Detection of malondialdehyde DNA adducts in human colorectal mucosa: relationship with diet and the presence of adenomas. Cancer Epidemiol Biomark Prev 2002;11:267-73.
70. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric Carcinoma N Engl J Med 1991;325:1127-31.
71. Ward JM, Fox JG, Anver MR, et al. Chronic active hepatitis and associated liver tumours in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst 1994;86:1222-7.
72. Singh R, Leuratti C, Josyula S, et al. Lobe-specific increases in malondialdehyde DNA adduct formation in the livers of mice following infection with Helicobacter hepaticus. Carcinogenesis 2001;22:1281-7.
73. Everett SM, Singh R, Leuratti C, et al. Levels of malondialdehyde- deoxyguanosine in the gastric mucosa: relationship with lipid peroxidation, ascorbic acid and Helicobacter pylori. Cancer Epidemiol. Biomark Prev 2001;10:369-376.
74. Kadlubar FF, Anderson KE, Haussermann S, et al. Comparison of DNA adduct levels associated with oxidative stress in human pancreas Mutation Res (Fundamental and Molecular Mechanisms of Mutagenesis) 1998;405:125-33.
75. Kochetkov NK, Shibaev VN, Kost AA. New reaction of adenine and cytosine derivatives, potentially useful for nucleic acid modifications. Tetrahedron Lett 1971;12:1993-6.
76. Nair J, Barbin A, Velic I, Bartsch H. Etheno DNA-base adducts from endogenous reactive species. Mutation Res (Fundamental and Molecular Mechanisms of Mutagenesis) 1999;424:59-69.
77. Nair J, Carmichael PI, Fernando RC, Phillips DH, Strain HJ, Bartsch H. Lipid peroxidation-induced etheno-DNA adducts in liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Cancer Epidemiol. Biomark Prev 1998;7:435-40.
78. Nair J, Gal A, Tamir S, Tannenbaum SR, Wogan GN, Bartsch H. Etheno adducts in spleen DNA of SJL mice stimulated to overproduce nitric oxide. Carcinogenesis 1998;19:2081-4.
79. Fang JL, Vaca CE, Valsta LM, Mutanen M. Determination of DNA adducts of malonaldehyde in humans: effects of dietary fatty acid composition. Carcinogenesis 1996;17:1035-40.
80. 32P-Postlabeling determination of DNA adducts of malonaldehyde in humans: total white blood cells and breast tissue. Carcinogenesis 1995;16:1847-51.
81. Nair J, Vaca CE, Velic I, Mutanen M, Valsta LM, Bartsch H. High dietary ω-6 polyunsaturated fatty acids drastically increase the formation of etheno-DNA base adducts in white blood cells of female subjects. Cancer Epidemiol Biomark Prev 1997;6:597-601.
82. Lin PH, Nakamura J, Yamaguchi S, Asakura S, Swenberg JA. Aldehydic DNA lesions induced by catechol estrogens in calf thymus DNA. Carcinogenesis 2003;24:1133-41.
83. Wang MY, Liehr JG. Induction by estrogens of lipid peroxidation and lipid peroxide-derived malonaldehyde-DNA adducts in male Syrian hamsters: role of lipid peroxidation in estrogen-induced kidney carcinogenesis. Carcinogenesis 1995;16:1941-5.
84. Shuker DE, Atkin W, Bingham SA, Leuratti, C, Singh R. Malondialdehyde-DNA adducts in relation to diet and disease risk-a brief overview of recent results. IARC Sci Publ 2002;156:475-80.
85. Farinati F, Cardin R, Degan P, et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Rad Biol Med 1999;27:1284-91.
86. Umemura T, Kai S, Hasegawa R, et al. Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine-induced hepato- and cholangiocarcinogenesis in mice by green tea infusion. Carcinogenesis 2003;24:1105-9.
87. Chen LW, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001;93:1872-9.
88. Rao AV, Agarwal S. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. Nutr Cancer 1998;31:199-203.
89. Gedik CM, Boyle SP, Wood SG, Vaughan NJ, Collins AR. Oxidative stress in humans: validation of biomarkers of DNA damage. Carcinogenesis 2002;23:1441-6.
90. Shoji H, Oguchi S, Shimizu T, Yamashiro Y. Effect of human breast milk on urinary 8-hydroxy-2′-deoxyguanosine excretion in infants. Pediatr Res 2003;53:850-2.
91. Akagi S, Nagake Y, Kasahara J, et al. Significance of 8-hydroxy-2′-deoxyguanosine levels in patients with chronic renal failure. Nephrology 2003;8:192-5.
92. Kristenson M, Kucinskiene Z, Schafer-Elinder L, Leanderson P, Tagesson C. Lower serum levels of beta-carotene in Lithuanian men are accompanied by higher urinary excretion of the oxidative DNA adduct, 8-hydroxydeoxyguanosine. The LiVicordia study. Nutrition 2003;19:11-5.
93. Kensler TW, Gange SJ, Egner PA, et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomark Prev 1997;8:603-10.
94. Kensler TW, He X, Otieno M, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomark Prev 1998;2:127-34.
95. 1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999;91:347-54.
96. Egner PA, Wang JB, Zhu YR, et al. Chlorophyllin intervention redues aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci USA 2001;98:14601-6.
97. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD. Development of cancer chemopreventive agents: oltipraz as a paradigm Chem Res Tox 1999;12:113-26.
98. Sharma RA. The advancement of cancer chemoprevention by revision of clinical trial strategies. Panminerva Med 2002;44:41-5.
99. Sharma RA. Cancer chemoprevention: a clinical reality. J Royal Soc Med 2000;93:518-20.